Safe sequencing system

ABSTRACT

The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.

CLAIM OF PRIORITY

This application is a continuation of U.S. patent application Ser. No.15/240,034, filed on Aug. 18, 2016, which is a divisional of U.S. patentapplication Ser. No. 15/090,773, filed on Apr. 5, 2016, which is adivisional application of Ser. No. 14/814,030 filed Jul. 30, 2015, whichis a divisional of Ser. No. 14/111,715 filed Apr. 29, 2014, which is a371 International Application of PCT/US2012/033207 filed Apr. 12, 2012,which claims priority to U.S. Provisional Application No. 61/484,482filed May 10, 2011 and U.S. Provisional Application No. 61/476,150 filedon Apr. 15, 2011, the entire contents of each of which are herebyincorporated by reference.

GOVERNMENT SUPPORT CLAUSE

This invention was made with government support under grant numberCA062924, CA057345, CA043460, HHSN261004433009C awarded by the NationalInstitutes of Health. The government has certain rights in theinvention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on May 18, 2021, isnamed “44807-0017008 Sequence-Listing” and is 16,384 bytes in size.

TECHNICAL FIELD OF THE INVENTION

This invention is related to the area of nucleic acid sequencing. Inparticular, it relates to manipulative and analytic steps for analyzingand verifying the products of low frequency events.

BACKGROUND OF THE INVENTION

Genetic mutations underlie many aspects of life and death—throughevolution and disease, respectively. Accordingly, their measurement iscritical to several fields of research. Luria and Delbruck's classicfluctuation analysis is a prototypic example of the insights intobiological processes that can be gained simply by counting the number ofmutations in carefully controlled experiments (1). Counting de novomutations in humans, not present in their parents, have similarly led tonew insights into the rate at which our species can evolve (2,3).Similarly, counting genetic or epigenetic changes in tumors can informfundamental issues in cancer biology (4). Mutations lie at the core ofcurrent problems in managing patients with viral diseases such as AIDSand hepatitis by virtue of the drug-resistance they can cause (5,6).Detection of such mutations, particularly at a stage prior to theirbecoming dominant in the population, will likely be essential tooptimize therapy. Detection of donor DNA in the blood of organtransplant patients is an important indicator of graft rejection anddetection of fetal DNA in maternal plasma can be used for prenataldiagnosis in a non-invasive fashion (7,8). In neoplastic diseases, whichare all driven by somatic mutations, the applications of rare mutantdetection are manifold; they can be used to help identify residualdisease at surgical margins or in lymph nodes, to follow the course oftherapy when assessed in plasma, and perhaps to identify patients withearly, surgically curable disease when evaluated in stool, sputum,plasma, and other bodily fluids (9-11).

These examples highlight the importance of identifying rare mutationsfor both basic and clinical research. Accordingly, innovative ways toassess them have been devised over the years. The first methods involvedbiologic assays based on prototrophy, resistance to viral infection ordrugs, or biochemical assays (1, 12-18). Molecular cloning andsequencing provided a new dimension to the field, as it allowed the typeof mutation, rather than simply its presence, to be identified (19-24).Some of the most powerful of these newer methods are based on DigitalPCR, in which individual molecules are assessed one-by-one (25). DigitalPCR is conceptually identical to the analysis of individual clones ofbacteria, cells, or virus, but is performed entirely in vitro withdefined, inanimate reagents. Several implementations of Digital PCR havebeen described, including the analysis of molecules arrayed inmulti-well plates, in polonies, in microfluidic devices, and inwater-in-oil emulsions (25-30). In each of these technologies, mutanttemplates are identified through their binding to oligonucleotidesspecific for the potentially mutant base.

Massively parallel sequencing represents a particularly powerful form ofDigital PCR in that hundreds of millions of template molecules can beanalyzed one-by-one. It has the advantage over conventional Digital PCRmethods in that multiple bases can be queried sequentially and easily inan automated fashion. However, massively parallel sequencing cannotgenerally be used to detect rare variants because of the high error rateassociated with the sequencing process. For example, with the commonlyused Illumina sequencing instruments, this error rate varies from˜1%(31,32) to −0.05% (33,34), depending on factors such as the readlength (35), use of improved base calling algorithms (36-38) and thetype of variants detected (39). Some of these errors presumably resultfrom mutations introduced during template preparation, during thepre-amplification steps required for library preparation and duringfurther solid-phase amplification on the instrument itself. Other errorsare due to base mis-incorporation during sequencing and base-callingerrors. Advances in base-calling can enhance confidence (e.g., (36-39)),but instrument-based errors are still limiting, particularly in clinicalsamples wherein the mutation prevalence can be 0.01% or less (11). Inthe work described below, we show how templates can be prepared and thesequencing data obtained from them can be more reliably interpreted, sothat relatively rare mutations can be identified with commerciallyavailable instruments.

There is a continuing need in the art to improve the sensitivity andaccuracy of sequence determinations for investigative, clinical,forensic, and genealogical purposes.

SUMMARY OF THE INVENTION

According to one aspect of the invention a method analyzes nucleic acidsequences. A unique identifier (UID) nucleic acid sequence is attachedto a first end of each of a plurality of analyte nucleic acid fragmentsto form uniquely identified analyte nucleic acid fragments. Nucleotidesequence of a uniquely identified analyte nucleic acid fragment isredundantly determined, wherein determined nucleotide sequences whichshare a UID form a family of members. A nucleotide sequence isidentified as accurately representing an analyte nucleic acid fragmentwhen at least 1% of members of the family contain the sequence.

According to another aspect of the invention a method analyzes nucleicacid sequences. A unique identifier sequence (UID) is attached to afirst end of each of a plurality of analyte DNA fragments using at leasttwo cycles of amplification with first and second primers to formuniquely identified analyte DNA fragments. The UIDs are in excess of theanalyte DNA fragments during amplification. The first primers comprise afirst segment complementary to a desired amplicon; a second segmentcontaining the UID; and a third segment containing a universal primingsite for subsequent amplification. The second primers comprise auniversal priming site for subsequent amplification. Each cycle ofamplification attaches one universal priming site to a strand. Theuniquely identified analyte DNA fragments are amplified to form a familyof uniquely identified analyte DNA fragments from each uniquelyidentified analyte DNA fragment. Nucleotide sequences of a plurality ofmembers of the family are determined.

Another aspect of the invention is a method to analyze DNA usingendogenous unique identifier sequences (UIDs). Fragmented analyte DNA isobtained comprising fragments of 30 to 2000 bases, inclusive. Each endof a fragment forms an endogenous UID for the fragment. Adapteroligonucleotides are attached to ends of the fragments to form adaptedfragments. Fragments representing one or more selected genes areoptionally enriched by means of capturing a subset of the fragmentsusing capture oligonucleotides complementary to selected genes in theanalyte DNA or by amplifying fragments complementary to selected genes.The adapted fragments are amplified using primers complementary to theadapter oligonucleotides to form families of adapted fragments.Nucleotide sequence is determined of a plurality of members of a family.Nucleotide sequences of the plurality of members of the family arecompared. A nucleotide sequence is identified as accurately representingan analyte DNA fragment when at least a 1% of members of the familycontain the sequence.

Still another aspect of the invention is a composition comprisingpopulation of primer pairs, wherein each pair comprises a first andsecond primer for amplifying and identifying a gene or gene portion. Thefirst primer comprises a first portion of 10-100 nucleotidescomplementary to the gene or gene portion and a second portion of 10 to100 nucleotides comprising a site for hybridization to a third primer.The second primer comprises a first portion of 10-100 nucleotidescomplementary to the gene or gene portion and a second portion of 10 to100 nucleotides comprising a site for hybridization to a fourth primer.Interposed between the first portion and the second portion of thesecond primer is a third portion consisting of 2 to 4000 nucleotidesforming a unique identifier (UID). The unique identifiers in thepopulation have at least 4 different sequences. The first and secondprimers are complementary to opposite strands of the gene or geneportion. A kit may comprise the population of primers and the third andfourth primers complementary to the second portions of each of the firstand second primers.

These and other embodiments which will be apparent to those of skill inthe art upon reading the specification provide the art with tools andmethods for sensitively and accurately determining nucleic acid featuresor sequences.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Essential Elements of Safe-SeqS. In the first step, eachfragment to be analyzed is assigned a unique identification (UID)sequence (metal hatch or stippled bars). In the second step, theuniquely tagged fragments are amplified, producing UID-families, eachmember of which has the same UID. A super-mutant is defined as aUID-family in which ≥95% of family members have the same mutation.

FIG. 2. Safe-SeqS with Endogenous UIDs Plus Capture. The sequences ofthe ends of each fragment produced by random shearing (variously shadedbars) serve as the unique identifiers (UIDs). These fragments areligated to adapters (earth hatched and cross hatched bars) so they cansubsequently be amplified by PCR. One uniquely identifiable fragment isproduced from each strand of the double-stranded template; only onestrand is shown. Fragments of interest are captured on a solid phasecontaining oligonucleotides complementary to the sequences of interest.Following PCR amplification to produce UID-families with primerscontaining 5′ “grafting” sequences (adhesive filled and light stippledbars), sequencing is performed and super-mutants are defined as in FIG.1.

FIG. 3. Safe-SeqS with Exogenous UIDs. DNA (sheared or unsheared) isamplified with a set of gene-specific primers. One of the primers has arandom DNA sequence (e.g., a set of 14 N's) that forms the uniqueidentifier (UID; variously shaded bars), located 5′ to its gene-specificsequence, and both have sequences that permit universal amplification inthe next step (earth hatched and cross hatched bars). Two UID assignmentcycles produce two fragments—each with a different UID—from eachdouble-stranded template molecule, as shown. Subsequent PCR withuniversal primers, which also contain “grafting” sequences (adhesivefilled and light stippled bars), produces UID-families which aredirectly sequenced. Super-mutants are defined as in the legend to FIG.1.

FIGS. 4A-4B. Single Base Substitutions Identified by Conventional andSafe-SeqS Analysis. The exogenous UID strategy depicted in FIG. 3 wasused to produce PCR fragments from the CTNNB1 gene of three normal,unrelated individuals. Each position represents one of 87 possiblesingle base substitutions (3 possible substitutions/base×29 basesanalyzed). These fragments were sequenced on an Illumina GA IIxinstrument and analyzed in the conventional manner (FIG. 4A) or withSafe-SeqS (FIG. 4B). Safe-SeqS results are displayed on the same scaleas conventional analysis for direct comparison; the inset is a magnifiedview. Note that most of the variants identified by conventional analysisare likely to represent sequencing errors, as indicated by their highfrequency relative to Safe-SeqS and their consistency among unrelatedsamples.

FIG. 5. Safe-SeqS with endogenous UIDs plus inverse PCR. The sequence ofthe ends of each fragment produced by random shearing serve as uniqueidentifiers (UIDs; variously shaded bars). These fragments are ligatedto adapters (earth hatched and cross hatched bars) as in a standardIllumina library preparation. One uniquely tagged fragment is producedfrom each strand of the double-stranded template; only one strand isshown. Following circularization with a ligase, inverse PCR is performedwith gene-specific primers that also contain 5′ “grafting” sequences(adhesive filled and lightly stippled bars). This PCR producesUID-families which are directly sequenced. Super-mutants are defined asin FIG. 1.

FIG. 6A-6B. Single base substitutions position vs. error frequency inoligonucleotides synthesized with phosphoramidites and Phusion. Arepresentative portion of the same 31-base DNA fragment synthesized withphosphoramidites (FIG. 6A) or Phusion polymerase (FIG. 6B) was analyzedby Safe-SeqS. The means and standard deviations for seven independentexperiments of each type are plotted. There was an average of 1,721±383and 196±143 SBS super-mutants identified in thephosphoramidite-synthesized and Phusion-generated fragments,respectively. The y-axis indicates the fraction of the total errors atthe indicated position. Note that the errors in thephosphoramidite-synthesized DNA fragment were consistent among the sevenreplicates, as would be expected if the errors were systematicallyintroduced during the synthesis itself. In contrast, the errors in thePhusion-generated fragments appeared to be heterogeneous among samples,as expected from a stochastic process (Luria and Delbruck, Genetics 28:491-511, 1943).

FIG. 7. UID-family member distribution. The exogenous UID strategydepicted in FIG. 3 was used to produce PCR fragments from a region ofCTNNB1 from three normal, unrelated individuals (Table 2B); arepresentative example of the UID-families with ≤300 members (99% oftotal UID-families) generated from one individual is shown. The y-axisindicates the number of different UID-families that contained the numberof family members shown on the x-axis.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have developed an approach, called “Safe-SeqS” (fromSafe-Sequencing System). In one embodiment it involves two basic steps(FIG. 1). The first is the assignment of a Unique Identifier (UID) toeach nucleic acid template molecule to be analyzed. The second is theamplification of each uniquely tagged template, so that many daughtermolecules with the identical sequence are generated (defined as aUID-family). If a mutation pre-existed in the template molecule used foramplification, that mutation should be present in a certain proportion,or even all, of daughter molecules containing that UID (barring anysubsequent replication or sequencing errors). A UID-family in whichevery family member (or a certain predetermined proportion) has anidentical mutation is called a “super-mutant.” Mutations not occurringin the original templates, such as those occurring during theamplification steps or through errors in base-calling, should not giverise to super-mutants, i.e., will not be present at the pre-determinedfrequency in a UID family. In other embodiments, amplification is notnecessary.

The approach can be employed for any purpose where a very high level ofaccuracy and sensitivity is required from sequence data. As shown below,the approach can be used to assess the fidelity of a polymerase, theaccuracy of in vitro synthesized nucleic acid synthesis, and theprevalence of mutations in nuclear or mitochondrial nucleic acids ofnormal cells. The approach may be used to detect and/or quantifymosaicsm and somatic mutations. Fragments of nucleic acids may beobtained using a random fragment forming technique such as mechanicalshearing, sonicating, or subjecting nucleic acids to other physical orchemical stresses. Fragments may not be strictly random, as some sitesmay be more susceptible to stresses than others. Endonucleases thatrandomly or specifically fragment may also be used to generatefragments. Size of fragments may vary, but desirably will be in rangesbetween 30 and 5,000 basepairs, between 100 and 2,000, between 150 and1,000, or within ranges with different combinations of these endpoints.Nucleic acids may be, for example, RNA or DNA. Modified forms of RNA orDNA may also be used.

Attachment of an exogenous UID to an analyte nucleic acids fragment maybe performed by any means known in the art, including enzymatic,chemical, or biologic. One means employs a polymerase chain reaction.Another means employs a ligase enzyme. The enzyme may be mammalian orbacterial, for example. Ends of fragments may be repaired prior tojoining using other enzymes such as Klenow Fragment of T4 DNAPolymerase. Other enzymes which may be used for attaching are otherpolymerase enzymes. An UID may be added to one or both ends of thefragments. A UID may be contained within a nucleic acid molecule thatcontains other regions for other intended functionality. For example, auniversal priming site may be added to permit later amplification.Another additional site may be a region of complementarity to aparticular region or gene in the analyte nucleic acids. A UID may befrom 2 to 4,000, from 100 to 1000, from 4 to 400, bases in length, forexample.

UIDs may be made using random addition of nucleotides to form a shortsequence to be used as an identifier. At each position of addition, aselection from one of four deoxyribonucleotides may be used.Alternatively a selection from one of three, two, or onedeoxyribonucleotides may be used. Thus the UID may be fully random,somewhat random, or non-random in certain positions. Another manner ofmaking UIDs utilizes pre-determined nucleotides assembled on a chip. Inthis manner of making, complexity is attained in a planned manner. Itmay be advantageous to attach a UID to each end of a fragment,increasing the complexity of the UID population on fragments.

A cycle of polymerase chain reaction for adding exogenous UID refers tothe thermal denaturation of a double stranded molecule, thehybridization of a first primer to a resulting single strand, theextension of the primer to form a new second strand hybridized to theoriginal single strand. A second cycle refers to the denaturation of thenew second strand from the original single strand, the hybridization ofa second primer to the new second strand, and the extension of thesecond primer to form a new third strand, hybridized to the new secondstrand. Multiple cycles may be required to increase efficiency, forexample, when analyte is dilute or inhibitors are present.

In the case of endogenous UIDs, adapters can be added to the ends offragments by ligation. Complexity of the analyte fragments can bedecreased by a capture step, either on a solid phase or in liquid step.Typically the capture step will employ hybridization to probesrepresenting a gene or set of genes of interest. If on a solid phase,non-binding fragments are separated from binding fragments. Suitablesolid phases known in the art include filters, membranes, beads,columns, etc. If in a liquid phase, a capture reagent can be added whichbinds to the probes, for example through a biotin-avidin typeinteraction. After capture, desired fragments can be eluted for furtherprocessing. The order of adding adapters and capturing is not critical.Another means of reducing the complexity of the analyte fragmentsinvolves amplification of one or more specific genes or regions. One wayto accomplish this is to use inverse PCR. Primers can be used which aregene-specific, thus enriching while forming libraries. Optionally, thegene-specific primers can contain grafting sequences for subsequentattachment to a massively parallel sequencing platform.

Because endogenous UIDs provide a limited number of uniquepossibilities, depending on the fragment size and sequencing readlength, combinations of both endogenous and exogenous UIDs can be used.Introducing additional sequences when amplifying would increase theavailable UIDs and thereby increase sensitivity. For example, beforeamplification, the template can be split into 96 wells, and 96 differentprimers could be used during the amplification. This would effectivelyincrease the available UIDs 96-fold, because up to 96 templates with thesame endogenous UID could be distinguished. This technique can also beused with exogenous UIDs, so that each well's primers adds a unique,well-specific sequence to the amplification products. This can improvethe specificity of detection of rare templates.

Amplification of fragments containing a UID can be performed accordingto known techniques to generate families of fragments. Polymerase chainreaction can be used. Other amplification methods can also be used, asis convenient. Inverse PCR may be used, as can rolling circleamplification. Amplification of fragments typically is done usingprimers that are complementary to priming sites that are attached to thefragments at the same time as the Ms. The priming sites are distal tothe UIDs, so that amplification includes the UIDs. Amplification forms afamily of fragments, each member of the family sharing the same UID.Because the diversity of UIDs is greatly in excess of the diversity ofthe fragments, each family should derive from a single fragment moleculein the analyte. Primers used for the amplification may be chemicallymodified to render them more resistant to exonucleases. One suchmodification is the use of phosphorothioate linkages between one or more3′ nucleotides. Another employs boranophosphates.

Family members are sequenced and compared to identify any divergencieswithin a family. Sequencing is preferably performed on a massivelyparallel sequencing platform, many of which are commercially available.If the sequencing platform requires a sequence for “grafting,” i.e.,attachment to the sequencing device, such a sequence can be added duringaddition of UlDs or adapters or separately. A grafting sequence may bepart of a UID primer, a universal primer, a gene target-specific primer,the amplification primers used for making a family, or separate.Redundant sequencing refers to the sequencing of a plurality of membersof a single family.

A threshold can be set for identifying a mutation in an analyte. If the“mutation” appears in all members of a family, then it derives from theanalyte. If it appears in less than all members, then it may have beenintroduced during the analysis. Thresholds for calling a mutation may beset, for example, at 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,90%, 95%, 97%, 98%, or 100%. Thresholds will be set based on the numberof members of a family that are sequenced and the particular purpose andsituation.

In some embodiments, prior to amplification, the analyte DNA is treatedwith bisulfite to convert unmethylated cytosine bases to uracil. In someembodiments the number of families representing a first analyte DNAfragment is compared to number of families representing a second analyteDNA fragment to determine a relative concentration of a first analyteDNA fragment to a second analyte DNA fragment in the plurality ofanalyte DNA fragments.

Populations of primer pairs are used to attach exogenous UIDs. The firstprimer comprises a first portion of 10-100 nucleotides complementary tothe gene or gene portion and a second portion of 10 to 100 nucleotidescomprising a site for hybridization to a third primer. The second primercomprises a first portion of 10-100 nucleotides complementary to thegene or gene portion and a second portion of 10 to 100 nucleotidescomprising a site for hybridization to a fourth primer. Interposedbetween the first portion and the second portion of the second primer isa third portion consisting of 2 to 4,000 nucleotides forming a uniqueidentifier (UID). The unique identifiers in the population have at least4, at least 16, at least 64, at least 256, at least 1,024, at least4,096, at least 16,384, at least 65,536, at least 262,144, at least1,048,576, at least 4,194,304, at least 16,777,216, or at least67,108,864 different sequences. The first and second primers arecomplementary to opposite strands of the gene or gene portion. A kit canbe made containing both the primers for attaching exogenous UIDs as wellas amplification primers, i.e., the third and fourth primerscomplementary to the second portions of each of the first and secondprimers. The third and fourth primers can optionally contain additionalgrafting or indexing sequences. The UID may comprise randomly selectedsequences, pre-defined nucleotide sequences, or both randomly selectedsequences and pre-defined nucleotides. If both, these can be joinedtogether in blocks or interspersed.

The methods of analysis can be used to quantitate as well as todetermine a sequence. For example, the relative abundance of two analyteDNA fragments may be compared. The results described below in theexamples demonstrate that the Safe-SeqS approach can substantiallyimprove the accuracy of massively parallel sequencing (Tables 1 and 2).It can be implemented through either endogenous or exogenouslyintroduced UIDs and can be applied to virtually any sample preparationworkflow or sequencing platform. As demonstrated here, the approach caneasily be used to identify rare mutants in a population of DNAtemplates, to measure polymerase error rates, and to judge thereliability of oligonucleotide syntheses. One of the advantages of thestrategy is that it yields the number of templates analyzed as well asthe fraction of templates containing variant bases. Previously describedin vitro methods for the detection of small numbers of templatemolecules (e.g., (29,50)) allow the fraction of mutant templates to bedetermined but cannot determine the number of mutant and normaltemplates in the original sample.

It is of interest to compare Safe-SeqS to other approaches for reducingerrors in next-generation sequencing. As mentioned above, in thebackground of the invention, sophisticated algorithms to increase theaccuracy of base-calling have been developed (e.g., (36-39)). These cancertainly reduce false positive calls, but their sensitivity is stilllimited by artifactual mutations occurring during the PCR steps requiredfor library preparation as well as by (a reduced number of) base-callingerrors. For example, the algorithm employed in the current study usedvery stringent criteria for base-calling and was applied to shortread-lengths, but was still unable to reduce the error rate to less thanan average of 2.0×10⁻⁴ errors/bp. This error frequency is at least aslow as those reported with other algorithms. To improve sensitivityfurther, these base-calling improvements can be used together withSafe-SeqS. Travers et al. have described another powerful strategy forreducing errors (51). With this technology, both strands of eachtemplate molecule are sequenced redundantly after a number ofpreparative enzymatic steps. However, this approach can only beperformed on a specific instrument. Moreover, for many clinicalapplications, there are relatively few template molecules in the initialsample and evaluation of nearly all of them is required to obtain therequisite sensitivity. The approach described here with exogenouslyintroduced UIDs (FIG. 3) fulfills this requirement by coupling the UIDassignment step with a subsequent amplification in which few moleculesare lost. Our endogenous UID approaches (FIG. 2 and FIG. 5) and the onedescribed by Travers et al. are not ideally suited for this purposebecause of the inevitable losses of template molecules during theligation and other preparative steps.

How do we know that the mutations identified by conventional analyses inthe current study represent artifacts rather than true mutations in theoriginal templates? Strong evidence supporting this is provided by theobservation that the mutation prevalence in all but one experiment wassimilar—2.0×10⁻⁴ to 2.4×10⁻⁴ mutations/bp (Tables 1 and 2). Theexception was the experiment with oligonucleotides synthesized fromphosphoramidites, in which the error of the synthetic process wasapparently higher than the error rate of conventional Illumina analysiswhen used with stringent base-calling criteria. In contrast, themutation prevalence of Safe-SeqS varied much more, from 0.0 to 1.4×10⁻⁵mutations/bp, depending on the template and experiment. Moreover, themutation prevalence measured by Safe-SeqS in the most controlledexperiment, in which polymerase fidelity was measured (Table 2A), wasalmost identical to that predicted from previous experiments in whichpolymerase fidelity was measured by biological assays. Our measurementsof mutation prevalence in the DNA from normal cells are consistent withsome previous experimental data. However, estimates of these prevalencesvary widely and may depend on cell type and sequence analyzed (see SItext). We therefore cannot be certain that the few mutations revealed bySafe-SeqS represented errors occurring during the sequencing processrather than true mutations present in the original DNA templates.Potential sources of error in the Safe-SeqS process are described in theSI text.

Another potential application of Safe-SeqS is the minimization of PCRcontamination, a serious problem for clinical laboratories. Withendogenous or exogenous UID assignment, the UIDs of mutant templates cansimply be compared to those identified in prior experiments; theprobability that the same mutation from two independent samples wouldhave the same UID in different experiments is negligible when mutationsare infrequent. Additionally, with exogenous UIDs, a control experimentwith the same template but without the UID assigning PCR cycles (FIG. 3)can ensure that no DNA contamination is present in that templatepreparation; no template should be amplified in the absence of UIDassignment cycles and thus no PCR product of the proper size should beobserved.

Like all techniques, Safe-SeqS has limitations. For example, we havedemonstrated that the exogenous UIDs strategy can be used to analyze asingle amplicon in depth. This technology may not be applicable tosituations wherein multiple amplicons must be analyzed from a samplecontaining a limited number of templates. Multiplexing in the UIDassignment cycles (FIG. 3) may provide a solution to this challenge. Asecond limitation is that the efficiency of amplification in the UIDassignment cycles is critical for the success of the method. Clinicalsamples may contain inhibitors that reduce the efficiency of this step.This problem can presumably be overcome by performing more than twocycles in the UID assignment PCR step (FIG. 3), though this wouldcomplicate the determination of the number of templates analyzed. Thespecificity of Safe-SeqS is currently limited by the fidelity of thepolymerase used in the UID assignment PCR step, i.e., 8.8×10⁻⁷mutations/bp in its current implementation with two cycles. Increasingthe number of cycles in the UID assignment PCR step to five woulddecrease the overall specificity to ˜2×10⁻⁶ mutations/bp. However, thisspecificity can be increased by requiring more than one super-mutant formutation identification—the probability of introducing the sameartifactual mutation twice or three times would be exceedingly low([2×10⁻⁶]² or [2×10⁻⁶]³, respectively). In sum, there are several simpleways to perform Safe-SeqS variations and analysis variations to realizethe needs of specific experiments.

Luria and Delbruck, in their classic paper in 1943, wrote that their“prediction cannot be verified directly, because what we observe, whenwe count the number of resistant bacteria in a culture, is not thenumber of mutations which have occurred but the number of resistantbacteria which have arisen by multiplication of those which mutated, theamount of multiplication depending on how far back the mutationoccurred.” The Safe-SeqS procedure described here can verify suchpredictions because the number as well as the time of occurrence of eachmutation can be estimated from the data, as noted in the experiments onpolymerase fidelity. In addition to templates generated by polymerasesin vitro, the same approach can be applied to DNA from bacteria,viruses, and mammalian cells. We therefore expect that this strategywill provide definitive answers to a variety of important biomedicalquestions.

The above disclosure generally describes the present invention. Allreferences disclosed herein are expressly incorporated by reference. Amore complete understanding can be obtained by reference to thefollowing specific examples which are provided herein for purposes ofillustration only, and are not intended to limit the scope of theinvention.

Example 1—Endogenous UIDs

UIDs, sometimes called barcodes or indexes, can be assigned to nucleicacid fragments in many ways. These include the introduction of exogenoussequences through PCR (40,41) or ligation (42,43). Even more simply,randomly sheared genomic DNA inherently contains UIDs consisting of thesequences of the two ends of each sheared fragment (FIG. 2 and FIG. 5).Paired-end sequencing of these fragments yields UID-families that can beanalyzed as described above. To employ such endogenous UIDs inSafe-SeqS, we used two separate approaches: one designed to evaluatemany genes simultaneously and the other designed to evaluate a singlegene fragment in depth (FIG. 2 and FIG. 5, respectively).

For the evaluation of multiple genes, we ligated standard Illuminasequencing adapters to the ends of sheared DNA fragments to produce astandard sequencing library, then captured genes of interest on a solidphase (44). In this experiment, a library made from the DNA of ˜15,000normal cells was used, and 2,594 bp from six genes were targeted forcapture. After excluding known single nucleotide polymorphisms, 25,563apparent mutations, corresponding to 2.4×10⁻⁴±mutations/bp, were alsoidentified (Table 1). Based on previous analyses of mutation rates inhuman cells, at least 90% of these apparent mutations were likely torepresent mutations introduced during template and library preparationor base-calling errors. Note that the error rate determined here(2.4×10⁻⁴ mutations/bp) is considerably lower than usually reported inexperiments using the Illumina instrument because we used very stringentcriteria for base calling.

TABLE 1 Safe-SeqS with Endogenous UIDs Capture Inverse PCR ConventionalAnalysis High quality bp 106,958,863 1,041,346,645 Mean high quality bpread depth    38,620×    2,085,600× Mutations identified    25,563    234,352 Mutations/bp 2.4E−04 2.3E−04 Safe-SeqS Analysis High qualitybp 106,958,863 1,041,346,645 Mean high quality bp read depth    38,620×   2,085,600× UID-families    69,505      1,057 Average # ofmembers/UID-family       40      21,688 Median # of members/UID-family      19         4 Super-mutants identified        8         0Super-mutants/bp 3.5E−06         0.0

With Safe-SeqS analysis of the same data, we determined that 69,505original template molecules were assessed in this experiment (i.e.,69,505 UID-families, with an average of 40 members per family, wereidentified, Table 1). All of the polymorphic variants identified byconventional analysis were also identified by Safe-SeqS. However, only 8super-mutants were observed among these families, corresponding to3.5×10⁻⁶ mutations/bp. Thus Safe-SeqS decreased the presumptivesequencing errors by at least 70-fold.

Safe-SeqS analysis can also determine which strand of a template ismutated, thus an additional criteria for calling mutations could requirethat the mutation appears in only one or in both strands of theoriginally double stranded template. Massively parallel sequencers areable to obtain sequence information from both ends of a template in twosequential reads. (This type of sequencing experiment is called a“paired end” run on the Illumina platform, but similar experiments canbe done on other sequencing platforms where they may be called byanother name.) The two strands of a double stranded template can bedifferentiated by the observed orientation of the sequences and theorder in which they appear when sequence information is obtained fromboth ends. For example, a UID strand pair could consist of the followingtwo groups of sequences when each end of a template is sequenced insequential reads: 1) A sequence in the sense orientation that begins atposition 100 of chromosome 2 in the first read followed by a sequence inthe antisense orientation that begins at position 400 of chromosome 2 inthe second read; and 2) A sequence in the antisense orientation thatbegins at position 400 of chromosome 2 in the first read followed by asequence in the sense orientation that begins at position 100 ofchromosome 2 in the second read. In the capture experiment describedabove, 42,222 of 69,505 UIDs (representing 21,111 original doublestranded molecules) in the region of interest represented UID strandpairs. These 42,222 UIDs encompassed 1,417,838 bases in the region ofinterest. When allowing a mutation to only occur within UID strand pairs(whether in one or both strands), two super-mutants were observed,yielding a mutation rate of 1.4×10⁻⁶ super-mutants/bp. When requiringthat a mutation occur in only one strand of a UID strand pair, only onesuper-mutant was observed, yielding a mutation rate of 7.1×10⁻⁷super-mutants/bp. When requiring that a mutation occur in both strandsof a UID strand pair, only one super-mutant was observed, yielding amutation rate of 7.1×10⁻⁷ super-mutants/bp. Thus, requiring thatmutations occur in only one or in both strands of templates can furtherincrease the specificity of Safe-SeqS.

A strategy employing endogenous UIDs was also used to reduce falsepositive mutations upon deep sequencing of a single region of interest.In this case, a library prepared as described above from ˜1,750 normalcells was used as template for inverse PCR employing primerscomplementary to a gene of interest, so the PCR products could bedirectly used for sequencing (FIG. 5). With conventional analysis, anaverage of 2.3×10⁻⁴ mutations/bp were observed, similar to that observedin the capture experiment (Table 1). Given that only 1,057 independentmolecules from normal cells were assessed in this experiment, asdetermined through Safe-SeqS analysis, all mutations observed withconventional analysis likely represented false positives (Table 1). WithSafe-SeqS analysis of the same data, no super-mutants were identified atany position.

Example 2—Exogenous UIDs

Though the results described above show that Safe-SeqS can increase thereliability of massively parallel sequencing, the number of differentmolecules that can be examined using endogenous UIDs is limited. Forfragments sheared to an average size of 150 bp (range 125-175), 36 basepaired-end sequencing can evaluate a maximum of 7,200 differentmolecules containing a specific mutation (2 reads×2 orientations×36bases/read×50 base variation on either end of the fragment). Inpractice, the actual number of UIDs is smaller because the shearingprocess is not entirely random.

To make more efficient use of the original templates, we developed aSafe-SeqS strategy that employed a minimum number of enzymatic steps.This strategy also permitted the use of degraded or damaged DNA, such asfound in clinical specimens or after bisulfite-treatment for theexamination of cytosine methylation (45). As depicted in FIG. 3, thisstrategy employs two sets of PCR primers. The first set is synthesizedwith standard phosphoramidite precursors and contained sequencescomplementary to the gene of interest on the 3′ end and different tailsat the 5′ ends of both the forward and reverse primers. The differenttails allowed universal amplification in the next step. Finally, therewas a stretch of 12 to 14 random nucleotides between the tail and thesequence-specific nucleotides in the forward primer (40). The randomnucleotides form the UIDs. An equivalent way to assign UIDs tofragments, not used in this study, would employ 10,000 forward primersand 10,000 reverse primers synthesized on a microarray. Each of these20,000 primers would have gene-specific primers at their 3′-ends and oneof 10,000 specific, predetermined, non-overlapping UID sequences attheir 5′-ends, allowing for 10⁸ (i.e., [10⁴]²) possible UIDcombinations. In either case, two cycles of PCR are performed with theprimers and a high-fidelity polymerase, producing a uniquely tagged,double-stranded DNA fragment from each of the two strands of eachoriginal template molecule (FIG. 3). The residual, unused UID assignmentprimers are removed by digestion with a single-strand specificexonuclease, without further purification, and two new primers areadded. Alternatively or in addition to such digestion, one can use asilica column that selectively retains larger-sized fragments or one canuse solid phase reversible immobilization (SPRI) beads under conditionsthat selectively retain larger fragments to eliminate smaller,non-specific, amplification artifacts. This purification may potentiallyhelp in reducing primer-dimer accumulation in later steps. The newprimers, complementary to the tails introduced in the UID assignmentcycles, contain grafting sequences at their 5′ ends, permittingsolid-phase amplification on the Illumina instrument, andphosphorothioate residues at their 3′ ends to make them resistant to anyremaining exonuclease. Following 25 additional cycles of PCR, theproducts are loaded on the Illumina instrument. As shown below, thisstrategy allowed us to evaluate the majority of input fragments and wasused for several illustrative experiments.

Example 3—Analysis of DNA Polymerase Fidelity

Measurement of the error rates of DNA polymerases is essential for theircharacterization and dictates the situations in which these enzymes canbe used. We chose to measure the error rate of Phusion polymerase, asthis polymerase has one of the lowest reported error frequencies of anycommercially available enzyme and therefore poses a particular challengefor an in vitro-based approach. We first amplified a single human DNAtemplate molecule, comprising a segment of an arbitrarily chosen humangene, through 19 rounds of PCR. The PCR products from theseamplifications, in their entirety, were used as templates for Safe-SeqSas described in FIG. 3. In seven independent experiments of this type,the number of UID-families identified bysequencing was 624,678±421,274,which is consistent with an amplification efficiency of 92±9.6% perround of PCR.

The error rate of Phusion polymerase, estimated through cloning of PCRproducts encoding β-galactosidase in plasmid vectors and transformationinto bacteria, is reported by the manufacturer to be 4.4×10⁻⁷errors/bp/PCR cycle. Even with very high stringency base-calling,conventional analysis of the Illumina sequencing data revealed anapparent error rate of 9.1×10⁻⁶ errors/bp/PCR cycle, more than an orderof magnitude higher than the reported Phusion polymerase error rate(Table 2A). In contrast, Safe-SeqS of the same data revealed an errorrate of 4.5×10⁻⁷ errors/bp/PCR cycle, nearly identical to that measuredfor Phusion polymerase in biological assays (Table 2A). The vastmajority (>99%) of these errors were single base substitutions (Table3A), consistent with previous data on the mutation spectra created byother prokaryotic DNA polymerases (15,46,47).

TABLE 2A-2C Safe-SeqS with Exogenous UIDs Standard Mean Deviation 2A.Polymerase Fidelity Conventional analysis of 7 replicates High qualitybp 996,855,791 64,030,757 Total mutations identified 198,638 22,515Mutations/bp 2.0E−04 1.7E−05 Calculated Phusion Error Rate(errors/bp/cycle) 9.1E−06 7.7E−07 Safe-SeqS analysis of 7 replicatesHigh quality bp 996,855,791 64,030,757 UID-families 624,678 421,274Members/UID-family 107 122 Total super-mutants identified 197 143Super-mutants/bp 9.9E−06 2.3E−06 Calculated Phusion Error Rate(errors/bp/cycle) 4.5E−07 1.0E−07 2B. CTNNB1 mutations in DNA fromnormal human cells Conventional analysis of 3 individuals High qualitybp 559,334,774 66,600,749 Total mutations identified 118,488 11,357Mutations/bp 2.1E−04 1.6E−05 Safe-SeqS analysis of 3 individuals Highquality bp 559,334,774 66,600,749 UID-families 374,553 263,105Members/UID-family 68 38 Total super-mutants identified 99 78Super-mutants/bp 9.0E−06 3.1E−06 2C. Mitochondrial mutations in DNA fromnormal human cells Conventional analysis of 7 individuals High qualitybp 147,673,456 54,308,546 Total mutations identified 30,599 12,970Mutations/bp 2.1E−04 9.4E−05 Safe-SeqS analysis of 7 individuals Highquality bp 147,673,456 54,308,546 UID-families 515,600 89,985Members/UID-family 15 6 Total super-mutants identified 135 61Super-mutants/bp 1.4E−05 6.8E−06

TABLE 3A-C Fraction of Single Base Substitutions, Insertions, andDeletions with Exogenous UIDs Standard Mean Deviation 3A. PolymeraseFidelity Conventional analysis of 7 replicates Total mutationsidentified 198,638 22,515 Fraction of mutations represented by  99% 0%single base substitutions Fraction of mutations represented by deletions  1% 0% Fraction of mutations represented by insertions   0% 0%Safe-SeqS analysis of 7 replicates Total super-mutants identified 197143 Fraction of super-mutants represented by  99% 2% single basesubstitutions Fraction of super-mutants represented by deletions   1% 2%Fraction of super-mutants represented by insertions   0% 0% 3B. CTNNB1mutations in DNA from normal human cells Conventional analysis of 3individuals Total mutations identified 118,488 11,357 Fraction ofmutations represented by  97% 0% single base substitutions Fraction ofmutations represented by deletions   3% 0% Fraction of mutationsrepresented by insertions   0% 0% Safe-SeqS analysis of 3 individualsTotal super-mutants identified 99 78 Fraction of super-mutantsrepresented by 100% 1% single base substitutions Fraction ofsuper-mutants represented by deletions  0% 1% Fraction of super-mutantsrepresented by insertions  0% 0% 3C. Mitochondrial mutations in DNA fromnormal human cells Conventional analysis of 7 individuals Totalmutations identified 30,599 12,970 Fraction of mutations represented by 98% 1% single base substitutions Fraction of mutations represented bydeletions  2% 1% Fraction of mutations represented by insertions  0% 0%Safe-SeqS analysis of 7 individuals Total super-mutants identified 13561 Fraction of super-mutants represented by  99% 1% single basesubstitutions Fraction of super-mutants represented by deletions  1% 1%Fraction of super-mutants represented by insertions  0% 0%

Safe-SeqS also allowed a determination of the total number of distinctmutational events and an estimation of PCR cycle in which the mutationoccurred. There were 19 cycles of PCR performed in wells containing asingle template molecule in these experiments. If a polymerase erroroccurred in cycle 19, there would be only one super-mutant produced(from the strand containing the mutation). If the error occurred incycle 18 there should be two super-mutants (derived from the mutantstrands produced in cycle 19), etc. Accordingly, the cycle in which theerror occurred is related to the number of super-mutants containing thaterror. The data from seven independent experiments demonstrate arelatively consistent number of observed total polymerase errors(2.2±1.1×10⁻⁶ distinct mutations/bp), in good agreement with theexpected number of observations from simulations (1.5±0.21×10⁻⁶ distinctmutations/bp). The data also show a highly variable timing of occurrenceof polymerase errors among experiments (Table 4), as predicted fromclassic fluctuation analysis (1). This kind of information is difficultto derive using conventional analysis of the same next-generationsequencing data, in part because of the prohibitively high apparentmutation rate noted above.

TABLE 4A-4G Observed and Expected Number of Errors Generated by PhusionPolymerase Expected (mean ± SD) Observed * 4A. Experiment 1 Mutationsrepresented by 1 super-mutant 10  19 ± 3.7 Mutations represented by 2super-mutants 8 5.8 ± 2.3 Mutations represented by 3 super-mutants 4 1.3± 1.1 Mutations represented by 4 super-mutants 4 1.8 ± 1.3 Mutationsrepresented by 5 super-mutants 2 0.61 ± 0.75 Mutations represented by 6super-mutants 2 0.22 ± 0.44 Mutations represented by 7 super-mutants 00.01 ± 0.10 Mutations represented by 8 super-mutants 0 0.87 ± 0.86Mutations represented by 9 super-mutants 2 0.28 ± 0.51 Mutationsrepresented by 10 super-mutants 0 0.14 ± 0.38 Mutations representedby >10 super-mutants 3 1.5 ± 2.7 Distinct mutations 35  32 ± 4.2 4B.Experiment 2   Mutations represented by 1 super-mutant 19  23 ± 4.1Mutations represented by 2 super-mutants 5 9.5 ± 2.8 Mutationsrepresented by 3 super-mutants 4 2.7 ± 1.6 Mutations represented by 4super-mutants 7 2.7 ± 1.7 Mutations represented by 5 super-mutants 20.88 ± 0.94 Mutations represented by 6 super-mutants 1 0.40 ± 0.60Mutations represented by 7 super-mutants 3 0.16 ± 0.42 Mutationsrepresented by 8 super-mutants 1 0.99 ± 1.0  Mutations represented by 9super-mutants 1 0.39 ± 0.68 Mutations represented by 10 super-mutants 00.17 ± 0.43 Mutations represented by >10 super-mutants 9 1.8 ± 3.4Distinct mutations 52  43 ± 5.1 4C. Experiment 3 Mutations representedby 1 super-mutant 7  17 ± 3.4 Mutations represented by 2 super-mutants 95.4 ± 2.0 Mutations represented by 3 super-mutants 4 1.2 ± 1.1 Mutationsrepresented by 4 super-mutants 4 1.7 ± 1.4 Mutations represented by 5super-mutants 2 0.50 ± 0.70 Mutations represented by 6 super-mutants 00.17 ± 0.45 Mutations represented by 7 super-mutants 1 0.03 ± 0.17Mutations represented by 8 super-mutants 0 0.59 ± 0.74 Mutationsrepresented by 9 super-mutants 0 0.24 ± 0.50 Mutations represented by 10super-mutants 1 0.07 ± 0.29 Mutations represented by >10 super-mutants 51.5 ± 2.6 Distinct mutations 33  28 ± 3.7 4D. Experiment 4   Mutationsrepresented by 1 super-mutant 7  15 ± 3.7 Mutations represented by 2super-mutants 8 4.1 ± 1.7 Mutations represented by 3 super-mutants 20.70 ± 0.74 Mutations represented by 4 super-mutants 1 1.5 ± 1.3Mutations represented by 5 super-mutants 3 0.21 ± 0.52 Mutationsrepresented by 6 super-mutants 2 0.08 ± 0.27 Mutations represented by 7super-mutants 1 0.0 ± 0.0 Mutations represented by 8 super-mutants 20.65 ± 0.77 Mutations represented by 9 super-mutants 2 0.17 ± 0.43Mutations represented by 10 super-mutants 0 0.05 ± 0.22 Mutationsrepresented by >10 super-mutants 1 0.92 ± 2.1  Distinct mutations 29  23± 3.2 4E. Experiment 5   Mutations represented by 1 super-mutant 9  23 ±4.1 Mutations represented by 2 super-mutants 6 9.5 ± 2.8 Mutationsrepresented by 3 super-mutants 5 2.7 ± 1.6 Mutations represented by 4super-mutants 3 2.7 ± 1.7 Mutations represented by 5 super-mutants 60.88 ± 0.94 Mutations represented by 6 super-mutants 2 0.40 ± 0.60Mutations represented by 7 super-mutants 1 0.16 ± 0.42 Mutationsrepresented by 8 super-mutants 2 0.99 ± 1.0  Mutations represented by 9super-mutants 2 0.39 ± 0.68 Mutations represented by 10 super-mutants 30.17 ± 0.43 Mutations represented by >10 super-mutants 7 1.8 ± 3.4Distinct mutations 46  43 ± 5.1 4F. Experiment 6 Mutations representedby 1 super-mutant 4 6.7 ± 2.8 Mutations represented by 2 super-mutants 71.5 ± 1.2 Mutations represented by 3 super-mutants 1 0.10 ± 0.33Mutations represented by 4 super-mutants 2 0.60 ± 0.82 Mutationsrepresented by 5 super-mutants 0 0.07 ± 0.26 Mutations represented by 6super-mutants 0 0.01 ± 0.10 Mutations represented by 7 super-mutants 10.0 ± 0.0 Mutations represented by 8 super-mutants 1 0.39 ± 0.60Mutations represented by 9 super-mutants 0 0.01 ± 0.10 Mutationsrepresented by 10 super-mutants 0 0.0 ± 0.0 Mutations represented by >10super-mutants 2 0.50 ± 1.1  Distinct mutations 18 9.9 ± 1.4 4G.Experiment 7 Mutations represented by 1 super-mutant 8 2.9 ± 1.6Mutations represented by 2 super-mutants 2 0.61 ± 0.79 Mutationsrepresented by 3 super-mutants 0 0.04 ± 0.24 Mutations represented by 4super-mutants 0 0.41 ± 0.59 Mutations represented by 5 super-mutants 10.01 ± 0.10 Mutations represented by 6 super-mutants 0 0.0 ± 0.0Mutations represented by 7 super-mutants 0 0.0 ± 0.0 Mutationsrepresented by 8 super-mutants 0 0.14 ± 0.35 Mutations represented by 9super-mutants 0 0.01 ± 0.10 Mutations represented by 10 super-mutants 00.0 ± 0.0 Mutations represented by >10 super-mutants 0 0.32 ± 0.93Distinct mutations 11  4.5 ± 0.62 *See SI Text for details of thesimulations

Example 4—Analysis of Oligonucleotide Composition

A small number of mistakes during the synthesis of oligonucleotides fromphoshoramidite precursors are tolerable for most applications, such asroutine PCR or cloning. However, for synthetic biology, wherein manyoligonucleotides must be joined together, such mistakes present a majorobstacle to success. Clever strategies for making the gene constructionprocess more efficient have been devised (48,49), but all suchstrategies would benefit from more accurate synthesis of theoligonucleotides themselves. Determining the number of errors insynthesized oligonucleotides is difficult because the fraction ofoligonucleotides containing errors can be lower than the sensitivity ofconventional next-generation sequencing analyses.

To determine whether Safe-SeqS could be used for this determination, weused standard phosphoramidite chemistry to synthesize an oligonucleotidecontaining 31 bases that were designed to be identical to that analyzedin the polymerase fidelity experiment described above. In the syntheticoligonucleotide, the 31 bases were surrounded by sequences complementaryto primers that could be used for the UID assignment steps of Safe-SeqS(FIG. 3). By performing Safe-SeqS on ˜300,000 oligonucleotides, we foundthat there were 8.9±0.28×10⁻⁴ super-mutants/bp and that these errorsoccurred throughout the oligonucleotides (FIG. 6A). The oligonucleotidescontained a large number of insertion and deletion errors, representing8.2±0.63% and 25±1.5% of the total super-mutants, respectively.Importantly, both the position and nature of the errors were highlyreproducible among seven independent replicates of this experimentperformed on the same batch of oligonucleotides (FIG. 6A). This natureand distribution of errors had little in common with that of the errorsproduced by Phusion polymerase (FIG. 6 B and Table 5), which weredistributed in the expected stochastic pattern among replicateexperiments. The number of errors in the oligonucleotides synthesizedwith phosphoramidites was ˜60 times higher than in the equivalentproducts synthesized by Phusion polymerase. These data, in toto,indicate that the vast majority of errors in the former were generatedduring their synthesis rather than during the Safe-SeqS procedure.

TABLE 5 Phosphoramidite- vs Phusion-Synthesized DNA: Transitions vsTransversions Comparison Exp. Exp. Exp. Exp. Exp. Exp. Exp. Standard 1 23 4 5 6 7 Average Deviation Phosphoramidites Transition super-mutants:496 509 471 396 323 273 470 420 92 Transversion super-mutants: 1494 14991521 1154 944 907 1626 1306 298 p-value* 3.4E-05 Phusion Transitionsuper-mutants: 63 275 127 5 87 182 103 120 87 Transversionsuper-mutants: 14 124 77 12 57 191 63 77 63 p-value* 0.08 *p-values werecalculated using a two-tailed paired t-test

Does Safe-SeqS preserve the ratio of mutant:normal sequences in theoriginal templates? To address this question, we synthesized two 31-baseoligonucleotides of identical sequence with the exception of nt 15(50:50 C/G instead of T) and mixed them at nominal mutant/normalfractions of 3.3% and 0.33%. Through Safe-SeqS analysis of theoligonucleotide mixtures, we found that the ratios were 2.8% and 0.27%,respectively. We conclude that the UID assignment and amplificationprocedures used in Safe-SeqS do not greatly alter the proportion ofvariant sequences and thereby provide a reliable estimate of thatproportion when unknown. This conclusion is also supported by thereproducibility of variant fractions when analyzed in independentSafe-SeqS experiments (FIG. 6A).

Example—5 Analysis of DNA Sequences from Normal Human Cells

The exogenous UID strategy (FIG. 3) was then used to determine theprevalence of rare mutations in a small region of the CTNNB1 gene from100,000 normal human cells from three unrelated individuals. Throughcomparison with the number of UID-families obtained in the Safe-SeqSexperiments (Table 2B), we calculated that the majority (78±9.8%) of theinput fragments were converted into UID-families. There was an averageof 68 members/UID-family, easily fulfilling the required redundancy forSafe-SeqS (FIG. 7). Conventional analysis of the Illumina sequencingdata revealed an average of 118,488±11,357 mutations among the ˜560 Mbof sequence analyzed per sample, corresponding to an apparent mutationprevalence of 2.1±0.16×10⁻⁴ mutations/bp (Table 2B). Only an average of99±78 super-mutants were observed in the Safe-SeqS analysis. The vastmajority (>99%) of super-mutants were single base substitutions and thecalculated mutation rate was 9.0±3.1×10⁻⁶ mutations/bp (Table 3B).Safe-SeqS thereby reduced the apparent frequency of mutations in genomicDNA by at least 24-fold (FIG. 4).

One possible strategy to increase the specificity of Safe-SeqS is toperform the library amplification (and possibly the UID assignmentcycles) in multiple wells. This can be accomplished in as few as 2 or asmany as 384 wells using standard PCR plates, or scaled up to many morewells when using a microfluidic device (thousands to millions). Whenperformed this way, indexing sequences can be introduced into thetemplates that are unique to the wells in which the template isamplified. Rare mutations, thus, should give rise to two super-mutants(i.e., one from each strand), both with the same well index sequence.When performing Safe-SeqS with exogenous UIDs on the CTNNB1 templatesdescribed above and diluted into 10 wells (each well yielding templatesamplified with a different index sequence), the mutation rate wasfurther reduced from 9.0±3.1×10⁻⁶ to 3.7±1.2×10⁻⁶ super-mutants/bp.Thus, analyzing templates in multiple compartments—in a manner thatyields differentially encoded templates based on the compartment inwhich templates were amplified—may be an additional strategy to increasethe specificity of Safe-SeqS.

Example 6—Analysis of DNA Sequences from Mitochondrial DNA

We applied the identical strategy to a short segment of mitochondrialDNA in 1,000 cells from each of seven unrelated individuals.Conventional analysis of the Illumina sequencing libraries produced withthe Safe-SeqS procedure (FIG. 3) revealed an average of 30,599±12,970mutations among the ˜150 Mb of sequence analyzed per sample,corresponding to an apparent mutation prevalence of 2.1±0.94×10⁻⁴mutations/bp (Table 2C). Only 135±61 super-mutants were observed in theSafe-SeqS analysis. As with the CTNNB1 gene, the vast majority ofmutations were single base substitutions, though occasional single basedeletions were also observed (Table 3C). The calculated mutation rate inthe analyzed segment of mtDNA was 1.4±0.68×10⁻⁵ mutations/bp (Table 2C).Thus, Safe-SeqS thereby reduced the apparent frequency of mutations ingenomic DNA by at least 15-fold.

Example 7—Materials and Methods

Endogenous UIDs. Genomic DNA from human pancreas or culturedlymphoblastoid cells was prepared using Qiagen kits. The pancreas DNAwas used for the capture experiment and the lymphoblastoid cells wereused for the inverse PCR experiment. DNA was quantified by opticalabsorbance and with qPCR. DNA was fragmented to an average size of ˜200bp by acoustic shearing (Covaris), then end-repaired, A-tailed, andligated to Y-shaped adapters according to standard Illumina protocols.The ends of each template molecule provide endogenous UIDs correspondingto their chromosomal positions. After PCR-mediated amplification of thelibraries with primer sequences within the adapters, DNA was captured(1) with a filter containing 2,594 nt corresponding to six cancer genes.After capture, 18 cycles of PCR were performed to ensure sufficientamounts of template for sequencing on an Illumina GA IIx instrument.

For the inverse PCR experiments (FIG. 5), we ligated custom adapters(IDT, Table 6) instead of standard Y-shaped Illumina adapters to shearedcellular DNA. These adapters retained the region complementary to theuniversal sequencing primer but lacked the grafting sequences requiredfor hybridization to the Illumina GA IIx flow cell. The ligated DNA wasdiluted into 96 wells and the DNA in each column of 8 wells wasamplified with a unique forward primer containing one of 12 indexsequences at its 5′ end plus a standard reverse primer (Table 6).Amplifications were performed using Phusion HotStart I (NEB) in 50 uLreactions containing 1× Phusion HF buffer, 0.5 mM dNTPs, 0.5 uM eachforward and reverse primer (both 5′-phosphorylated), and 1U of Phusionpolymerase. The following cycling conditions were used: one cycle of 98°C. for 30 s; and 16 cycles of 98° C. for 10 s, 65° C. for 30 s, and 72°C. for 30 s. All 96 reactions were pooled and then purified using aQiagen MinElute PCR Purification Kit (cat. no. 28004) and a QIAquick GelExtraction kit (cat. no. 28704). To prepare the circular templatesnecessary for inverse PCR, DNA was diluted to ˜1 ng/uL and ligated withT4 DNA Ligase (Enzymatics) for 30 min at room temperature in a 600 uLreaction containing 1× T4 DNA Ligation Buffer and 18,000 U of T4 DNALigase. The ligation reaction was purified using a Qiagen MinElute kit.Inverse PCR was performed using Phusion Hot Start I on 90 ng of circulartemplate distributed in twelve 50 uL reactions, each containing 1×Phusion HF Buffer, 0.25 mM dNTPs, 0.5 uM each of KRAS forward andreverse primers (Table 6) and 1 U of Phusion polymerase. TheKRAS-specific primers both contained grafting sequences forhybridization to the Illumina GA IIx flow cell (Table 6). The followingcycling conditions were used: one cycle of 98° C. for 2 min; and 37cycles of 98° C. for 10 s, 61° C. for 15 s, and 72° C. for 10 s. Thefinal purification was performed with a NucleoSpin Extract II kit(Macherey-Nagel) and eluted in 20 uL NE Buffer. The resulting DNAfragments contained UIDs composed of three sequences: two endogenousones, represented by the two ends of the original sheared fragments plusthe exogenous sequence introduced during the indexing amplification. As12 exogenous sequences were used, this increased the number of distinctUIDs by 12-fold over that obtained without exogenous UIDs. This numbercould easily be increased by using a greater number of distinct primers.

TABLE 6 Oligonucleotides Used Font Legend: Symbol Legend:REGION COMPLEMENTARY TO TEMPLATES /5Phos/ = 5′ PhosphateTEMPLATE-SPECIFIC UID SEQUENCE * = Phosphorothioate linkageUNIVERSAL SEQUENCE EXPERIMENT-SPECIFIC INDEX SEQUENCEILLUMINA GRAFTING PRIMERS (FOR HYBRIDIZATION TO FLOW CELL)Sequence (SEQ ID NO: 1-81, respectively) Endogenous UIDs CaptureAdapter-strand 1 /5Phos/GATCGGAAGAGCGGTTCAGCAGGAATGCCGAGAdapter-strand 2 ACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-forAATGATACGGCGACCACCGAGATCTACACACACTCTTTCCCTACACGAC GCTCTTCCGAT*C*TWhole Genome Amplification-revCAAGCAGAAGACGGCATACGAGATCTCGGCATTCCTGCTGAACCGCTCT TCCGAT*C*TPost-Capture Amplification-forAATGATACGGCGACCACCGAGATCTACACACACTCTTTCCCTACACGAC GCTCTTCCGAT*C*TPost-Capture Amplification-revCAAGCAGAAGACGGCATACGAGATCTCGGCATTCCTGCTGAACCGCTCT TCCGAT*C*TSequencing Primer, Read 1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(Illumina; SanDiego, CA) Sequencing Primer, Read 2CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT (Illumina; SanDiego, CA) Inverse PCRAdapter-strand 1 /5Phos/GATCGGAAGAGCGGTTCAGCAGGAATGCCGAGAdapter-strand 2 ACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-1CGTGATACACTCTTTCCCTACACGACGCTCTTCCGAT*C*T WholeGenome Amplification-for-2 ACATCGACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-3GCCTAAACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-4/TGGTCAACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-5CACTGTACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-6ATTGGCACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-7GATCTGACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-8TCAAGTACACTCTTTCCCTACACGACGCTCTTCCGAT*C*T WholeGenome Amplification-for-9 CTGATCACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-10AAGCTAACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-11GTAGCCACACTCTTTCCCTACACGACGCTCTTCCGAT*C*TWhole Genome Amplification-for-12TACAAGACACTCTTTCCCTACACGACGCTCTTCCGAT*C*T Whole Genome Amplification-rev/5Phos/CTCGGCATTCCTGCTGAACCGCTCTTCCGAT*C*T Inverse PCR-antisenseAATGATACGGCGACCACCGAGATCTACAC CAGCAGGCCTTATAATAAAA ATAATGAInverse PCR-for CAAGCAGAAGACGGCATACGAGAT TGACTGAATATAAACTTGTGGTAGT TGSequencing Primer 1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT(to read internal sequences) Sequencing Primer 2CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT (to read internal sequences)Index Primer 1 (to read experiment indexes)CGGAAGAGCGTCGTGTAGGGAAAGAGTGTIndex Primer 2 (to read experiment indexes)CGGAAGAGCGGTTCAGCAGGAATGCCGAG Exogenous UIDs PolymeraseFidelityDigital PCR Amplification-for GGTTACAGGCTCATGATGTAACCDigital PCR Amplification-rev GATACCAGCTTGGTAATGGCAUID Assignment Amplification-for CGACGTAAAACGACGGCCAGT

GGTTACAGGCTCATG ATGTAACC UID Assignment Amplification-revCACACAGGAAACAGCTATGACCATGGATACCAGCTTGGTAATGGCALibrary Amplification-for-1AATGATACGGCGACCACCGAGATCTACACCGTGATCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-2AATGATACGGCGACCACCGAGATCTACACACATCGCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-3AATGATACGGCGACCACCGAGATCTACACGCCTAACGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-4AATGATACGGCGACCACCGAGATCTACACTGGTCACGACGTAAAACGAC GGCA*G*TLibrary Amplification-for-5AATGATACGGCGACCACCGAGATCTACACCACTGTCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-6AATGATACGGCGACCACCGAGATCTACACATTGGCCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-7AATGATACGGCGACCACCGAGATCTACACGATCTGCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-8AATGATACGGCGACCACCGAGATCTACACTCAAGTCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-9AATGATACGGCGACCACCGAGATCTACACCTGATCCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-10AATGATACGGCGACCACCGAGATCTACACAAGCTACGACGTAAAACGAC GGCCA*G*TLibrary Amplification-revCAAGCAGAAGACGGCATACGAGATCACACAGGAAACAGCTATGACCA*T *GSequencing Primer (to read UID and CGACGTAAAACGACGGCCAGTinternal sequences) Index Primer (to read experiment indexes)ACTGGCCGTCGTTTTACGTCG CTNNB1 mutations in DNA from normal human cellsUID Assignment Amplification-for CGACGTAAAACGACGGCCAGT

GCAGCAACAGTCTT ACCTGGACT Library Amplification-forAATGATACGGCGACCACCGAGATCTACACCGACGTAAAACGACGGCCA* G*TLibrary Amplification-rev-1 ATCACGCACACAGGAAACAGCTATGACCA*T*GLibrary Amplification-rev-2CAAGCAGAAGACGGCATACGAGATCGATGTCACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-3CAAGCAGAAGACGGCATACGAGATTGACCACACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-4CAAGCAGAAGACGGCATACGAGATGCCAATCACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-5CAAGCAGAAGACGGCATACGAGATCAGATCCACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-6CAAGCAGAAGACGGCATACGAGATACTTGACACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-7CAAGCAGAAGACGGCATACGAGATGATCAGCACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-8CAAGCAGAAGACGGCATACGAGATTAGCTTCACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-9CAAGCAGAAGACGGCATACGAGATGGCTACCACACAGGAAACAGCTATG ACCA*T*GLibrary Amplification-rev-10CAAGCAGAAGACGGCATACGACATCTTGTACACACAGGAAACAGCTATG ACCA*T*GSequencing Primer (to read UID and CGACGTAAAACGACGGCCAGTinternal sequences) Index Primer (to read experiment indexes)CATGGTCATAGCTGTTTCCTGTGTG Mitochondrial mutations in DNA fromnormal human cells UID Assignment Amplification-forCGACGTAAAACGACGGCCAGT

TTACCGAGAAAGCT CACAAGAA UID Assignment Amplification-revCACACAGGAAACAGCTATGACCATGATGCTAAGGCGAGGATGAAALibrary Amplification-for-1AATGATACGGCGACCACCGAGATCTACACACATCGCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-2AATGATACGGCGACCACCGAGATCTACACGCCTAACGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-3AATGATACGGCGACCACCGAGATCTACACTGGTCACGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-4AATGATACGGCGACCACCGAGATCTACACATTGGCCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-5AATGATACGGCGACCACCGAGATCTACACGATCTGCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-6AATGATACGGCGACCACCGAGATCTACACTCAAGTCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-for-7AATGATACGGCGACCACCGAGATCTACACCTGATCCGACGTAAAACGAC GGCCA*G*TLibrary Amplification-revCAAGCAGAAGACGGCATACGAGATCACACAGGAAACAGCTATGACCA*T *GSequencing Primer 1 (to read UIDs) CGACGTAAAACGACGGCCAGTSequencing Primer 2 (to read internal CCTAATTCCCCCCATCCTTAC sequences)Index Primer (to read experiment indexes) ACTGGCCGTCGTTTTACGTCGAnalysis of Phosphoramidite Oligonucleotide CompositionSynthesized template, wt GGTTACAGGCTCATGATGTAACCTCTGTGTCTTGGTG TAACTTTAAAAC ATATTTTTGCCATTACCAAGCTGGTATCSynthesized template, mut (S = 50/50 mix ofGGTTACAGGCTCATGATGTAACCTCTGTGTCTTGGTG S AACTTTAAAAC C and G)ATATTTTTGCCATTACCAAGCTGGTATC UID Assignment Amplification-forACACTCTTTCCCTACACGACGCTC

GGTGAGTCTGTGC AGGCAT UID Assignment Amplification-revCTCGAGCACTGTCCTGACTGAGACGATACCAGCTTGGTAATGGCA Library Amplification-forAATGATACGGCGACCACCGAGATCTACACCGTGATACACTCTTTCCCTA CACGACGC*T*CLibrary Amplification-revCAAGCAGAAGACGGCATACGAGATCTCGAGCACTGTCCTGACTGAG*A* CSequencing Primer (to read UID and ACACTCTTTCCCTACACGACGCTCinternal sequences)

Exogenous UIDs. Genomic DNA from normal human colonic mucosae or bloodlymphocytes was prepared using Qiagen kits. The DNA from colonic mucosaewas used for the experiments on CTNNB1 and mitochondrial DNA, while thelymphocyte DNA was used for the experiments on CTNNB1 and on polymerasefidelity. DNA was quantified with Digital PCR (2) using primers thatamplified single-copy genes from human cells (Analysis of PolymeraseFidelity and CTNNB1), qPCR (mitochondrial DNA), or by optical absorbance(oligonucleotides). Each strand of each template molecule was encodedwith a 12 or 14 base UID using two cycles of amplicon-specific PCR, asdescribed in the text and FIG. 3. The amplicon-specific primers bothcontained universal tag sequences at their 5′ ends for a lateramplification step. The UIDs constituted 12 or 14 random nucleotidesequences appended to the 5′ end of the forward amplicon-specificprimers (Table 6). These primers can generate 16.8 and 268 milliondistinct UIDs, respectively. It is important that the number of distinctUIDs greatly exceed the number of original template molecules tominimize the probability that two different original templates acquiredthe same UID. The UID assignment PCR cycles included Phusion Hot StartII (NEB) in a 45 uL reaction containing 1× Phusion HF buffer, 0.25 mMdNTPs, 0.5 uM each forward (containing 12-14 Ns) and reverse primers,and 2 U of Phusion polymerase. To keep the final templateconcentrations<1.5 ng/uL, multiple wells were used to create somelibraries. The following cycling conditions were employed: oneincubation of 98° C. for 30 s (to activate the Phusion Hot Start II);and two cycles of 98° C. for 10 s, 61° C. for 120 s, and 72° C. for 10s. To ensure complete removal of the first round primers, each well wasdigested with 60 U of a single strand DNA specific nuclease(Exonuclease-I; Enzymatics) at 37° C. for 1 hr. After a 5 minheat-inactivation at 98° C., primers complementary to the introduceduniversal tags (Table 6) were added to a final concentration of 0.5 uMeach. These primers contained two terminal phosphorothioates to makethem resistant to any residual Exonuclease-I activity. They alsocontained 5′ grafting sequences necessary for hybridization to theIllumina GA IIx flow cell. Finally, they contained an index sequencebetween the grafting sequence and the universal tag sequence. This indexsequence enables the PCR products from multiple different individuals tobe simultaneously analyzed in the same flow cell compartment of thesequencer. The following cycling conditions were used for the subsequent25 cycles of PCR: 98° C. for 10 s and 72° C. for 15 s. No intermediatepurification steps were performed in an effort to reduce the losses oftemplate molecules.

After the second round of amplification, wells were consolidated andpurified using a Qiagen QIAquick PCR Purification Kit (cat. no. 28104)and eluted in 50 uL EB Buffer (Qiagen). Fragments of the expected sizewere purified after agarose (mtDNA libraries) or polyacrylamide (allother libraries) gel electrophoresis. For agarose gel purification, theeight 6-uL aliquots were loaded into wells of a 2% Size Select Gel(Invitrogen) and bands of the expected size were collected in EB Bufferas specified by the manufacturer. For polyacrylamide gel purification,ten 5-uL aliquots were loaded into wells of a 10% TBE Polyacrylamide Gel(Invitrogen). Gel slices containing the fragments of interest wereexcised, crushed, and eluted essentially as described (3).

Analysis of Phusion polymerase fidelity. Amplification of a fragment ofhuman genomic DNA within the BMX (RefSeq Accession NM_203281.2) gene wasfirst performed using the PCR conditions described above. The templatewas diluted so that an average of one template molecule was present inevery 10 wells of a 96-well PCR plate. Fifty uL PCR reactions were thenperformed in 1× Phusion HF buffer, 0.25 mM dNTPs, 0.5 uM each forwardand reverse primers (Table 6), and 2 U of Phusion polymerase. Thecycling conditions were one cycle of 98° C. for 30 s; and 19 cycles of98° C. for 10 s, 61° C. for 120 s, and 72° C. for 10 s. The primers wereremoved by digestion with 60 U of Exonuclease-I at 37° C. for 1 hrfollowed by a 5 min heat-inactivation at 98° C. No purification of thePCR product was performed, either before or after Exonuclease-Idigestion. The entire contents of each well were then used as templatesfor the exogenous UIDs strategy described above.

Sequencing. Sequencing of all the libraries described above wasperformed using an Illumina GA IIx instrument as specified by themanufacturer. The total length of the reads used for each experimentvaried from 36 to 73 bases. Base-calling and sequence alignment wasperformed with the Eland pipeline (Illumina). Only high quality readsmeeting the following criteria were used for subsequent analysis: (i)the first 25 bases passed the standard Illumina chastity filter; (ii)every base in the read had a quality score≥20; and (iii)≤3 mismatches toexpected sequences. For the exogenous UID libraries, we additionallyrequired the UIDs to have a quality score≥30. We noticed a relativelyhigh frequency of errors at the ends of the reads in the endogenous UIDlibraries prepared with the standard Illumina protocol, presumablyintroduced during shearing or end-repair, so the first and last threebases of these tags were excluded from analysis.

Safe-SeqS analysis. High quality reads were grouped into UID-familiesbased on their endogenous or exogenous UIDs. Only UID-families with twoor more members were considered. Such UID-families included the vastmajority (>99%) of the sequencing reads. To ensure that the same datawas used for both conventional and Safe-SeqS analysis, we also excludedUID-families containing only one member from conventional analysis.Furthermore, we only identified a base as “mutant” in conventionalsequencing analysis if the same variant was identified in at least twomembers of at least one UID-family (i.e., two mutations) when comparingconventional analysis to that of Safe-SeqS with exogenous UIDs. Forcomparison with Safe-SeqS with endogenous UIDs, we required at least twomembers of each of two UID-families (i.e., four mutations) to identify aposition as “mutant” in conventional analysis. With either endogenous orexogenous UIDs, a super-mutant was defined as a UID-family in which ≥95%of members shared the identical mutation. Thus, UID-families with <20members had to be 100% identical at the mutant position, while a 5%combined replication and sequencing error rate was permitted inUID-families with more members. To determine polymerase fidelity usingSafe-SeqS, and to compare the results with previous analyses of Phusionpolymerase fidelity, it was necessary to realize that the previousanalyses would only detect mutations present in both strands of the PCRproducts (4). This would be equivalent to analyzing PCR productsgenerated with one less cycle with Safe-SeqS, and the appropriatecorrection was made in Table 2A. Unless otherwise specified, all valueslisted in the text and Tables represent means and standard deviations.

Example 8—Error-Generating Processes

Apparent mutations, defined as any base call that varies from theexpected base at a defined position, can result from a variety ofprocesses:

-   1. Mutations present in the template DNA. For templates derived from    normal human cells, these include mutations that were present in the    zygote, occurred later during embryonic and adult development, or    were present in a contaminant inadvertently introduced into the    sample. These mutations are expected to be present in both strands    of the relevant templates. If the mutation occurred only in the last    cell-cycle of a cell whose DNA was used as template, the mutation    would be present in only one strand of the template.-   2. Chemically-modified bases present in the templates. It has been    estimated that there are many thousands of oxidized bases present in    every human cell (5). When such DNA is amplified by Phusion    polymerase, an apparent mutation in one strand may result.-   3. Errors introduced during the shearing process required to    generate small fragmentsfor sequencing. Acoustic shearing generates    short-lived, high temperatures that can damage DNA.-   4. Errors introduced during end-repair of the sheared fragments. The    source of these errors can be polymerase infidelity or through    incorporation of chemically-modified bases in the dNTPs used for    polymerization.-   5. Errors introduced by other enzymatic steps, particularly if the    enzymes are impure and contaminated with nucleases, polymerases, or    ligases.-   6. Errors introduced during PCR amplification to prepare the    libraries for capturing orfor inverse PCR.-   7. Errors during PCR after capturing or during inverse PCR    amplification.-   8. Errors introduced into the UID assignment cycles of Safe-SeqS    (FIG. 3).-   9. Errors introduced into the library amplification cycles of    Safe-SeqS performed with exogenous UIDs. Note that if UID assignment    primers from process #8 are not completely removed, they could    potentially amplify DNA fragments containing errors introduced    during these cycles, creating a new super-mutant.-   10. Errors introduced into the first bridge-PCR cycle on the    Illumina flow cell. If amplification is inefficient, an error    introduced into the second bridge-PCR cycle could also result in a    cluster containing a mutation in most of its component molecules.-   11. Errors in base-calling.

Example 9—Achieving Accuracy with Safe-SeqS

With conventional sequencing-by-synthesis approaches, all theerror-producing processes described above are relevant, resulting in arelatively high number of false-positive mutation calls (Tables 1 and2). Safe-SeqS minimizes the number of false-positive mutation calls inseveral ways. Safe-SeqS with exogenous UIDs results in the fewestfalse-positive mutation calls because it requires the fewest enzymaticsteps. With exogenous UIDs, error-generating processes #3 to #7 arecompletely eliminated because these steps aren't performed. Safe-SeqSwith exogenous UIDs also drastically reduces errors resulting fromerror-generating processes #10 and #11 because of the way the data isanalyzed.

After Safe-SeqS with exogenous UIDs, the only false-positive errorsremaining should be those introduced during the UID assignment PCRcycles (error-generating process #8) or residual UID-containing primersduring the library amplification cycles (error-generating process #9).The errors from error-generating process #8 can theoretically beeliminated by requiring at least two super-mutants to identify aposition as “mutant.” This requirement is reasonable because everypre-existing mutation in a double stranded DNA template should give riseto two super-mutants, one from each strand. Furthermore, thisrequirement would eliminate error-generating process #2 (damaged basesin the original templates) because such bases, when copied, should giverise to only one super-mutant. Finally, errors generated during thelibrary amplification cycles (process #9) will not be amplified byresidual UID-containing primers if those primers are completely removed,such as performed here with excess Exonuclease-I.

With endogenous UIDs, the mistakes introduced by processes #10 and #11are drastically reduced because of the way in which the data is analyzed(as with exogenous UIDs). Errors introduced in processes #2 to #7 can beminimized by requiring that a mutation be observed in at least twoUID-families, for the reasons stated in the paragraph above. With thisrequirement, few false-positive mutations, in theory, should beidentified.

In practice, the situation is complicated by the fact that the variousamplifications are not perfect, so every strand of every originaltemplate molecule is not recovered as a UID-family. This efficiency canvary from sample to sample, depending in part on the concentration ofinhibitors present in clinical samples. Moreover, with exogenous UIDs, apolymerase error during the library amplification step can create a newUID-family that wasn't represented in the UID assignment step. If thiserror occurred in a mutant template, an additional, artificialsuper-mutant would be created.

These factors can be managed by incorporating various additionalcriteria into the analyses. For example, one might require UID-familiesto contain more than two, five or ten members. Another requirement couldbe that the exogenous UIDs of super-mutants not be related to any otherUID in the library by a one-base difference. This would eliminateartificial super-mutants generated during the library amplificationsteps (noted in above paragraph). We routinely instituted thisrequirement in our Safe-SeqS analyses, but it made little difference(<1%) in the number of super-mutants identified. Specificity formutations can be further increased by requiring more than onesuper-mutant to identify a position as “mutant,” as described above forendogenous UIDs. When requiring multiple super-mutants, the specificitycan be even further increased by requiring that each strand of theoriginal double stranded template contain the mutation or, whenlibraries are amplified using multiple wells, that rare mutations sharean introduced sequence that identifies the well in which the mutations(i.e., one from each strand) were amplified. Such decisions involve theusual trade-off between specificity and sensitivity. In our experimentswith exogenous UIDs (Table 2), we required only one super-mutant toidentify a position as “mutant” and included all UID-families with morethan one member. As endogenous UIDs was associated with moreerror-generating processes than with exogenous UIDs, we required twosuper-mutants to identify a position as mutant in the experimentsreported in Table 1 and also included all UID-families with more thanone member.

Example 10—Mutation Prevalences in Normal Human Tissues

The experiments reported in Tables 1 and 2, in which >10,000 templateswere assessed, show that mutations are present in the nuclear DNA ofnormal human cells at a frequency of 3.5×10⁻⁶ to 9.0×10⁻⁶ mutants/bpdepending on the region analyzed. It is impossible to determine whetherthis low level represents genuine mutations present in the originaltemplates or the sum of genuine mutations plus artifactual mutationsfrom the error-generating processes described above. Mutationprevalences in human cells have not been widely investigated, in partbecause they are so infrequent. However, several clever techniques toidentify rare mutants have been devised and can in principle be used forcomparison. Unfortunately, estimates of human mutation prevalences varywidely, ranging from as many as 10⁻⁵ mutants/bp to as many as 10⁻⁸mutants/bp (6-12). In several of these studies, the estimates arecomplicated by the lack of data on the nature of the actualmutations—they could in some cases be caused by losses of wholechromosomes, in others by missense mutations, and in others mainly bynonsense mutations or small insertions or deletions. Additionally, thesestudies used various sources of normal cells and examined differentgenes, making direct comparisons difficult. Estimates of the prevalencesand rates of mitochondrial DNA mutations similarly vary (13-19). It willbe of interest in future work to analyze the same DNA templates andgenes with various technologies to determine the basis for thesedifferent estimates.

But let us assume that all of the mutations identified with Safe-SeqSrepresent genuine mutations present in the original DNA templates fromnormal cells. What does this tell us about the number of generationsthough which these cells have proceeded since the organism wasconceived? There is a simple relationship between mutation rate andmutation prevalence: the mutation prevalence equals the product of themutation rate and the number of generations that the cell has gonethrough since conception. The somatic mutation rate has been determinedin previous studies to be ˜10⁻⁹ mutants/bp/generation, though thisestimate also varies from study to study for reasons related to thosementioned above with respect to mutation prevalence. Combining thisliterature-derived estimate of mutation rate with our estimates ofmutation prevalence suggests that the normal cells analyzed(lymphocytes, lymphoblastoid cell lines or colonic mucosae) hadproceeded through 3,500 to 8,900 generations, representing cellsdividing every 3 to 7 days for the individuals examined in this study(average age 65 years).

Example 11—Computer Simulation of Polymerase-Introduced Errors

The timing of mutations introduced by polymerases greatly alters thefinal number of mutations observed (20). For example, two mutationswould differ in prevalence by ˜64-fold if introduced 6 cycles apart(2⁶). Because polymerases introduce mutations in a stochastic manner, asimple Monte Carlo method was employed for the simulations. In thesesimulations, we used the manufacturer's estimate of the Phusionpolymerase error rate with an appropriate adjustment for ability ofSafe-SeqS to detect mutations in only one strand (4). Note that errorsintroduced in cycle 19, as well as in the two UID assignment cycles,would result in changes in only one strand of the duplex—i.e., result inone super-mutant rather than two. In each experiment, we assumed thatthere was a constant efficiency of amplification given by the totalnumber of templates obtained at the end of the experiment (i.e., if thenumber of UID-families was N, then we assumed that the number oftemplates increased by a factor of N/2′⁹ in each cycle). One-thousandsimulations were performed for each of seven experiments, and theresults reported in Table 4.

REFERENCES (FOR EXAMPLES 8-11 ONLY)

-   1. Herman D S, et al. (2009) Filter-based hybridization capture of    subgenomes enables resequencing and copy-number detection. Nat    Methods 6:507-510.-   2. Vogelstein B & Kinzler K W (1999) Digital PCR. Proc Natl Acad Sci    USA 96:9236-9241.-   3. Chory J & Pollard J D, Jr. (2001) Separation of small DNA    fragments by conventional gel electrophoresis. Curr Protoc Mol Blot    Chapter 2:Unit2 7.-   4. Barnes W M (1992) The fidelity of Taq polymerase catalyzing PCR    is improved by an N-terminal deletion. Gene 112:29-35.-   5. Collins A R (1999) Oxidative DNA damage, antioxidants, and    cancer. Bioessays 21:238-246.-   6. Morley A A, Cox S, & Holliday R (1982) Human lymphocytes    resistant to 6-thioguanine increase with age. Mech Ageing Dev    19:21-26.-   7. Trainor K J, et al. (1984) Mutation frequency in human    lymphocytes increases with age. Mech Ageing Dev 27:83-86.-   8. Grist S A, McCarron M, Kutlaca A, Turner D R, & Morley A A (1992)    In vivo human somatic mutation: frequency and spectrum with age.    Mutat Res 266:189-196.-   9. Williams G T, Geraghty J M, Campbell F, Appleton Mass., &    Williams E D (1995)Normal colonic mucosa in hereditary non-polyposis    colorectal cancer shows no generalised increase in somatic mutation.    Br J Cancer 71:1077-1080.-   10. Campbell F, Appleton Mass., Shields C J, & Williams G T (1998)    No difference in stem cell somatic mutation between the background    mucosa of right- and left-sided sporadic colorectal carcinomas. J    Pathol 186:31-35.-   11. Araten D J, Nafa K, Pakdeesuwan K, & Luzzatto L (1999) Clonal    populations of hematopoietic cells with paroxysmal nocturnal    hemoglobinuria genotype and phenotype are present in normal    individuals. Proc Natl Acad Sci USA 96:5209-5214.-   12. Araten D J, et al. (2005) A quantitative measurement of the    human somatic mutation rate. Cancer Res 65:8111-8117.-   13. Monnat R J, Jr. & Loeb La. (1985) Nucleotide sequence    preservation of human mitochondrial DNA. Proc Natl Acad Sci USA    82:2895-2899.-   14. Bodenteich A, Mitchell L G, & Merril C R (1991) A lifetime of    retinal light exposure does not appear to increase mitochondrial    mutations. Gene 108:305-309.-   15. Howell N, Kubacka I, & Mackey D A (1996) How rapidly does the    human mitochondrial genome evolve? Am J Hum Genet 59:501-509.-   16. Khrapko K, et al. (1997) Mitochondrial mutational spectra in    human cells and tissues. Proc Natl Acad Sci USA 94:13798-13803.-   17. Heyer E, et al. (2001) Phylogenetic and familial estimates of    mitochondrial substitution rates: study of control region mutations    in deep-rooting pedigrees. Am J Hum Genet 69:1113-1126.-   18. Howell N, et al. (2003) The pedigree rate of sequence divergence    in the human mitochondrial genome: there is a difference between    phylogenetic and pedigree rates. Am J Hum Genet 72:659-670.-   19. Taylor R W, et al. (2003) Mitochondrial DNA mutations in human    colonic crypt stem cells. J Clin Invest 112:1351-1360.-   20. Luria S E & Delbruck M (1943) Mutations of Bacteria from Virus    Sensitivity to Virus Resistance. Genetics 28:491-511.

References (for all Except Examples 8-11)

The disclosure of each reference cited is expressly incorporated herein.

-   1. Luria S E & Delbruck M (1943) Mutations of Bacteria from Virus    Sensitivity to Virus Resistance. Genetics 28:491-511.-   2. Roach J C, et al. (2010) Analysis of genetic inheritance in a    family quartet by whole-genome sequencing. Science 328:636-639.-   3. Durbin R M, et al. (2010) A map of human genome variation from    population-scale sequencing. Nature 467:1061-1073.-   4. Shibata D (2011) Mutation and epigenetic molecular clocks in    cancer. Carcinogenesis 32:123-128.-   5. McMahon M A, et al. (2007) The HBV drug entecavir—effects on    HIV-1 replication and resistance. N Engl J Med 356:2614-2621.-   6. Eastman P S, et al. (1998) Maternal viral genotypic zidovudine    resistance and infrequent failure of zidovudine therapy to prevent    perinatal transmission of human immunodeficiency virus type 1 in    pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis    177:557-564.-   7. Chiu R W, et al. (2008) Noninvasive prenatal diagnosis of fetal    chromosomal aneuploidy by massively parallel genomic sequencing of    DNA in maternal plasma. Proc Natl Acad Sci USA 105:20458-20463.-   8. Fan H C, Blumenfeld Y J, Chitkara U, Hudgins L, & Quake S    R (2008) Noninvasive diagnosis of fetal aneuploidy by shotgun    sequencing DNA from maternal blood. Proc Natl Acad Sci USA    105:16266-16271.-   9. Hogue M O, et al. (2003) High-throughput molecular analysis of    urine sediment for the detection of bladder cancer by high-density    single-nucleotide polymorphism array. Cancer Res 63:5723-5726.-   10. Thunnissen F B (2003) Sputum examination for early detection of    lung cancer. J Clin Pathol 56:805-810.-   11. Diehl F, et al. (2008) Analysis of mutations in DNA isolated    from plasma and stool of colorectal cancer patients.    Gastroenterology 135:489-498.-   12. Barnes W M (1992) The fidelity of Taq polymerase catalyzing PCR    is improved by an N-terminal deletion. Gene 112:29-35.-   13. Araten D J, et al. (2005) A quantitative measurement of the    human somatic mutation rate. Cancer Res 65:8111-8117.-   14. Campbell F, Appleton M A, Shields C J, & Williams G T (1998) No    difference in stem cell somatic mutation between the background    mucosa of right- and left-sided sporadic colorectal carcinomas. J    Pathol 186:31-35.-   15. Tindall K R & Kunkel T A (1988) Fidelity of DNA synthesis by the    Thermus aquaticus DNA polymerase. Biochemistry 27:6008-6013.-   16. Kunkel T A (1985) The mutational specificity of DNA    polymerase-beta during in vitro DNA synthesis. Production of    frameshift, base substitution, and deletion mutations. J Biol Chem    260:5787-5796.-   17. van Dongen J J & Wolvers-Tettero Ill. (1991) Analysis of    immunoglobulin and T cell receptor genes. Part II: Possibilities and    limitations in the diagnosis and management of lymphoproliferative    diseases and related disorders. Clin Chim Acta 198:93-174.-   18. Grist S A, McCarron M, Kutlaca A, Turner D R, & Morley A    A (1992) In vivo human somatic mutation: frequency and spectrum with    age. Mutat Res 266:189-196.-   19. Liu Q & Sommer S S (2004) Detection of extremely rare alleles by    bidirectional pyrophosphorolysis-activated polymerization    allele-specific amplification (Bi-PAP-A): measurement of mutation    load in mammalian tissues. Biotechniques 36:156-166.-   20. Monnat R J, Jr. & Loeb La. (1985) Nucleotide sequence    preservation of human mitochondrial DNA. Proc Natl Acad Sci USA    82:2895-2899.-   21. Shi C, et al. (2004) LigAmp for sensitive detection of    single-nucleotide differences. Nat Methods 1:141-147.-   22. Keohavong P & Thilly W G (1989) Fidelity of DNA polymerases in    DNA amplification. Proc Natl Acad Sci USA 86:9253-9257.-   23. Sidransky D, et al. (1991) Identification of p53 gene mutations    in bladder cancers and urine samples. Science 252:706-709.-   24. Bielas J H & Loeb La. (2005) Quantification of random genomic    mutations. Nat Methods 2:285-290.-   25. Vogelstein B & Kinzler K W (1999) Digital PCR. Proc Natl Acad    Sci USA 96:9236-9241.-   26. Mitra R D, et al. (2003) Digital genotyping and haplotyping with    polymerase colonies. Proc Natl Acad Sci USA 100:5926-5931.-   27. Chetverina H V, Samatov T R, Ugarov V I, & Chetverin A B (2002)    Molecular colony diagnostics: detection and quantitation of viral    nucleic acids by in-gel PCR. Biotechniques 33:150-152, 154, 156.-   28. Zimmermann B G, et al. (2008) Digital PCR: a powerful new tool    for noninvasive prenatal diagnosis? Prenat Diagn 28:1087-1093.-   29. Dressman D, Yan H, Traverso G, Kinzler K W, & Vogelstein    B (2003) Transforming single DNA molecules into fluorescent magnetic    particles for detection and enumeration of genetic variations. Proc    Natl Acad Sci USA 100:8817-8822.-   30. Ottesen E A, Hong J W, Quake S R, & Leadbetter J R (2006)    Microfluidic digital PCR enables multigene analysis of individual    environmental bacteria. Science 314:1464-1467.-   31. Quail M A, et al. (2008) A large genome center's improvements to    the Illumina sequencing system. Nat Methods 5:1005-1010.-   32. Nazarian R, et al. (2010) Melanomas acquire resistance to    B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature    468:973-977.-   33. He Y, et al. (2010) Heteroplasmic mitochondrial DNA mutations in    normal and tumour cells. Nature 464:610-614.-   34. Gore A, et al. (2011) Somatic coding mutations in human induced    pluripotent stem cells. Nature 471:63-67.-   35. Dohm J C, Lottaz C, Borodina T, & Himmelbauer H (2008)    Substantial biases in ultra-short read data sets from    high-throughput DNA sequencing. Nucleic Acids Res 36:e105.-   36. Erlich Y, Mitra P P, delaBastide M, McCombie W R, & Hannon G    J (2008) Alta-Cyclic: a self-optimizing base caller for    next-generation sequencing. Nat Methods 5:679-682.-   37. Rougemont J, et al. (2008) Probabilistic base calling of Solexa    sequencing data. BMC Bioinformatics 9:431.-   38. Druley T E, et al. (2009) Quantification of rare allelic    variants from pooledgenomic DNA. Nat Methods 6:263-265.-   39. Vallania F L, et al. (2010) High-throughput discovery of rare    insertions and deletions in large cohorts. Genome Res 20:1711-1718.-   40. McCloskey M L, Stoger R, Hansen R S, & Laird C D (2007) Encoding    PCR products with batch-stamps and barcodes. Biochem Genet    45:761-767.-   41. Parameswaran P, et al. (2007) A pyrosequencing-tailored    nucleotide barcode design unveils opportunities for large-scale    sample multiplexing. Nucleic Acids Res 35:e130.-   42. Craig D W, et al. (2008) Identification of genetic variants    using bar-coded multiplexed sequencing. Nat Methods 5:887-893.-   43. Miner B E, Stoger R J, Burden A F, Laird C D, & Hansen R    S (2004) Molecularbarcodes detect redundancy and contamination in    hairpin-bisulfite PCR. Nucleic Acids Res 32:e135.-   44. Herman D S, et al. (2009) Filter-based hybridization capture of    subgenomes enables resequencing and copy-number detection. Nat    Methods 6:507-510.-   45. Jones P A & Baylin S B (2007) The epigenomics of cancer. Cell    128:683-692.-   46. de Boer J G & Ripley L S (1988) An in vitro assay for frameshift    mutations: hotspots for deletions of 1 bp by Klenow-fragment    polymerase share a consensus DNA sequence. Genetics 118:181-191.-   47. Eckert Kans. & Kunkel T A (1990) High fidelity DNA synthesis by    the Thermus aquaticus DNA polymerase. Nucleic Acids Res    18:3739-3744.-   48. Kosuri S, et al. (2010) Scalable gene synthesis by selective    amplification of DNApools from high-fidelity microchips. Nat    Biotechnol 28:1295-1299.-   49. Matzas M, et al. (2010) High-fidelity gene synthesis by    retrieval of sequence-verified DNA identified using high-throughput    pyrosequencing. Nat Biotechnol 28:1291-1294.-   50. Li J, et al. (2008) Replacing PCR with COLD-PCR enriches variant    DNA sequences and redefines the sensitivity of genetic testing. Nat    Med 14:579-584.-   51. Eid J, et al. (2009) Real-time DNA sequencing from single    polymerase molecules. Science 323:133-138.

We claim:
 1. A method of identifying a mutation comprising: a) attachingadapter oligonucleotides to ends of fragments of a plurality of analyteDNA of 30 to 2000 bases to form a plurality of adapted fragments,wherein said adapter oligonucleotides comprise exogenous uniqueidentifiers (UIDs); b) amplifying said adapted fragments such thatamplified fragments are generated, wherein said amplifying comprises theuse of a universal primer complementary to said adapteroligonucleotides; c) contacting said amplified fragments with at leastone gene-specific primer comprising a gene-specific region and agrafting sequence to generate further amplified fragments, wherein saidgrafting sequence is configured to attach to a massively parallelsequencing platform; d) redundantly sequencing said further amplifiedfragments to generate a plurality of sequencing reads; e) employing saidplurality of sequencing reads to: i) select endogenous UID sequencesimmediately adjacent to said exogenous UID sequences in each of saidplurality of sequencing reads, ii) select a combined UID at the ends ofeach of said plurality of sequencing reads, wherein each of saidcombined UIDs comprises said sequence of one of said endogenous UIDs andone of said exogenous UIDs, and iii) forming a plurality of combined UIDfamilies, wherein each combined UID family contains at least two familymembers; f) performing the following with sequencing analysis software:i) grouping said sequencing reads from each of said plurality ofcombined UID families based on their combined UIDs; and ii) identifyinga mutation in at least one of said fragments of said analyte DNA whengreater than 50% of said sequencing reads from said at least two familymembers in at least one of said plurality of combined UID families sharean identical mutation.
 2. The method of claim 1, further comprisingenriching for fragments representing one or more selected genes by meansof capturing a subset of the fragments using capture oligonucleotidescomplementary to said one or more selected genes in the analyte DNA. 3.The method of claim 1, further comprising enriching for fragmentsrepresenting one or more selected genes by means of amplifying fragmentscomplementary to the one or more selected genes.
 4. The method of claim3, wherein the step of attaching is prior to the step of enriching. 5.The method of claim 1, wherein said fragments are formed by shearing. 6.The method of claim 1, wherein each of said plurality of combined UIDfamilies contains at least five family members.
 7. The method of claim1, wherein each of said plurality of combined UID families contains atleast ten family members.
 8. The method of claim 1, wherein said greaterthan 50% is greater than 90%.